Department of Endocrinology and Metabolism, Turkiye Yuksek Ihtisas Education and Research Hospital, Kızılay sokak, 06100 Sihhiye, Ankara, Turkey.
Acta Diabetol. 2012 Dec;49 Suppl 1:S115-22. doi: 10.1007/s00592-011-0352-3. Epub 2011 Nov 19.
Rosiglitazone often results in weight gain. We hypothesized that rosiglitazone may modulate circulating levels of ghrelin and peptide YY(3-36) and this modulation may be related to weight-gaining effect of this agent. This study was designed as an open-label, randomized, controlled trial of 3-month duration. Women with newly diagnosed type 2 diabetes were studied. Twenty-eight of the 55 eligible participants were randomly assigned to receive rosiglitazone (4 mg/d). Twenty-seven patients with diabetes matched for age and body mass index served as controls on diet alone. We evaluated the effects of 3 months of rosiglitazone treatment on fasting peptide YY(3-36) and ghrelin levels, and anthropometric measurements. The 3-month administration of rosiglitazone reduced fasting plasma peptide YY(3-36) levels by 25%, the between-group difference was statistically significant. No effect of this thiazolidinedione compound on fasting ghrelin concentrations was observed at the end of study. The ghrelin/body mass index ratio also did not change significantly after treatment. Seventy-five percent of the women with diabetes complained of increased hunger at the end of study. Nevertheless, all subjects exhibited a decrease in fasting PYY levels after 3 months of rosiglitazone therapy, irrespective of the levels of hunger. There was no significant correlation between changes in peptide YY(3-36) and those in anthropometric parameters and insulin sensitivity at the end of the study. Rosiglitazone-induced decrease in fasting peptide YY(3-36) levels may in part contribute to orexigenic and weight-gaining effect of this thiazolidinedione derivative.
罗格列酮通常会导致体重增加。我们假设罗格列酮可能会调节循环中的 ghrelin 和肽 YY(3-36)水平，这种调节可能与该药物的增重作用有关。本研究设计为 3 个月的开放标签、随机、对照试验。研究对象为新诊断为 2 型糖尿病的女性。55 名符合条件的参与者中有 28 名被随机分配接受罗格列酮（4 毫克/天）治疗。27 名年龄和体重指数匹配的糖尿病患者单独接受饮食治疗作为对照组。我们评估了 3 个月罗格列酮治疗对空腹肽 YY(3-36)和 ghrelin 水平以及人体测量学指标的影响。3 个月的罗格列酮治疗使空腹血浆肽 YY(3-36)水平降低了 25%，组间差异具有统计学意义。研究结束时，这种噻唑烷二酮化合物对空腹 ghrelin 浓度没有影响。治疗后，ghrelin/体重指数比值也没有明显变化。研究结束时，75%的糖尿病女性抱怨饥饿感增加。然而，所有受试者在接受罗格列酮治疗 3 个月后，空腹 PYY 水平均下降，无论饥饿感如何。研究结束时，肽 YY(3-36)的变化与人体测量参数和胰岛素敏感性的变化之间没有显著相关性。罗格列酮诱导的空腹肽 YY(3-36)水平降低可能部分导致这种噻唑烷二酮衍生物的食欲增加和体重增加作用。
